메디테크인프라메드

비상장계속사업자

MEDITECH INFRAMED

박기수

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

메디테크인프라메드

Business Reg. No. 2158648328 · CEO 박기수

I.Investment Overview

Target메디테크인프라메드 (2158648328)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명메디테크인프라메드
영문명MEDITECH INFRAMED
대표자박기수
사업자등록번호2158648328
법인등록번호1101112865644
설립일2003.10.04

V.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW186.72021194.92022224.42023217.62024253.82025
영업이익100M KRW41202128.1202236.5202324.42024252025
순이익100M KRW34.3202120202234.3202320.5202428.22025
Item20252024202320222021
자산총계349.7억원318.3억원290.2억원263.9억원293.6억원
부채총계55.9억원52.8억원45억원53억원102.7억원
자본총계293.8억원265.6억원245.1억원210.8억원190.9억원
매출액253.8억원217.6억원224.4억원194.9억원186.7억원
영업이익25억원24.4억원36.5억원28.1억원41억원
순이익28.2억원20.5억원34.3억원20억원34.3억원

VI.Financial Ratios

FY2025 basis

9.87%

영업이익률

11.11%

순이익률

8.07%

ROA

9.6%

ROE

19.02%

부채비율

84.02%

자기자본비율

VII.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

메디테크인프라메드 투심보고서 | Alpha Lenz